Stocks and Investing Stocks and Investing
Thu, May 5, 2016
Wed, May 4, 2016
Tue, May 3, 2016

Paul Matteis Maintained (ALNY) at Buy with Decreased Target to $107 on, May 3rd, 2016


Published on 2024-10-25 12:32:24 - WOPRAI, Paul Matteis
  Print publication without navigation


Paul Matteis of Leerink Swann, Maintained "Alnylam Pharmaceuticals, Inc." (ALNY) at Buy with Decreased Target from $120 to $107 on, May 3rd, 2016.

Paul has made no other calls on ALNY in the last 4 months.



There are 3 other peers that have a rating on ALNY. Out of the 3 peers that are also analyzing ALNY, 0 agree with Paul's Rating of Hold.



These are the ratings of the 3 analyists that currently disagree with Paul


  • Keay Nakae of "Chardan Capital" Initiated at Strong Buy and Held Target at $93 on, Monday, April 4th, 2016
  • Anupam Rama of "JP Morgan" Upgraded from Hold to Buy and Decreased Target to $81 on, Friday, March 11th, 2016
  • Alethia Young of "Credit Suisse" Initiated at Buy and Held Target at $154 on, Wednesday, January 20th, 2016

Contributing Sources